| |
 |
AMA PRA Category 1 Credit(s)™
Release Date 12/6/2012
Expiration Date 12/31/2013 |
|
|
| |
|
|
| |
 |
Nezam Afdhal, MD
Beth Israel Deaconess
Medical Center
Boston, MA
|
|
| |
 |
|
| |
|
|
| |
 |
Kim Brown, MD
Henry Ford Hospital
Detroit, MI |
|
| |
|
|
| |
|
|
| |
 |
Jordan Feld, MD
Toronto Western Hospital
Liver Center
Toronto, Canada |
|
| |
|
|
| |
|
|
| |
 |
Michael Fried, MD
University of North Carolina
Chapel Hill, NC |
|
| |
|
|
| |
|
|
| |
 |
Ira Jacobson, MD
Weill Cornell Medical College
New York, NY |
|
| |
|
|
| |
|
|
| |
|
|
| |
 |
|
| |
|
|
| |
|
| |
|
|
|
|
|
Ira Jacobson, MD
Weill Cornell Medical College
New York, NY |
Ira M. Jacobson, MD, is Chief of the Division of Gastroenterology and Hepatology and Vincent Astor Professor of Medicine at Weill Cornell Medical College in New York City, and Attending Physician at New York Presbyterian Hospital. He is also Medical Director of the Center for the Study of Hepatitis C at Weill Cornell and Rockefeller University. After receiving his BS summa cum laude from Yale University in New Haven, Connecticut, and his medical degree from the Columbia University College of Physicians and Surgeons in New York City, Dr. Jacobson completed an internship and residency in internal medicine at the University of California, San Francisco. He completed a fellowship in gastroenterology at Massachusetts General Hospital and Harvard Medical School. He is board certified in internal medicine and gastroenterology.
In addition to maintaining an active practice with a focus on patients with liver disease, Dr. Jacobson has been an investigator in many trials on antiviral therapy for hepatitis B and C, including most of the pivotal trials on interferon-based therapy since the 1980s, and was the principal investigator of the WIN-R trial, the largest trial performed to date on HCV therapy. At Weill Cornell Medical College he directs a highly diversified clinical trials program dedicated to novel therapies for hepatitis B and C. He has authored more than 200 articles, chapters, and abstracts, which have appeared in New England Journal of Medicine, Annals of Internal Medicine, Hepatology, Journal of Hepatology, American Journal of Gastroenterology, Journal of Viral Hepatitis, and Clinical Gastroenterology and Hepatology, among other journals. He has edited two books, ERCP: Diagnostic and Therapeutic Applications and ERCP and Its Applications. In addition, he edited a volume on Hepatitis B for Clinics in Liver Disease, which appeared in 2007. He is an Associate Editor of Journal of Hepatology. Dr. Jacobson is a Fellow of the American College of Physicians, the American Gastroenterological Association, and the American College of Gastroenterology, and a member of the American Association for the Study of Liver Diseases, the American Society for Gastrointestinal Endoscopy, and the European Association for the Study of the Liver. He is a past president of the New York Society for Gastrointestinal Endoscopy and the New York Gastroenterological Association. He has served on both the Gastroenterology Board and the Transplant Hepatology Board of the American Board of Internal Medicine.
Speaker Disclosure:
Ira Jacobson, MD, has disclosed that he has received grants for clinical research from Abbott, Achillion, Anadys, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Novartis, Pfizer, Roche/Genentech, Shering/Merck, Tibotec/Janssen, and Vertex. He has participated on the speaker’s bureaus for Bristol Myers Squibb, Gilead, Roche/Genentech, Schering/Merck, and Vertex. In addition, he has served as a consultant for Abbott, Achillion, Boehringer Ingelheim, Bristol Myers Squibb, Enanta, Gilead, Glaxo Smithkline, Idenix, Kadmon, Novartis, Presidio, Roche/Genentech, Schering/Merck, Tibotech/Jenssen, and Vertex.
|
|
